Compositions and methods for the treatment of carboxyhemoglobinemia
View Patent ↗Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
1. A method of treating carboxyhemoglobinemia in a subject, comprising:
selecting a subject with carboxyhemoglobinemia; and
administering to the subject a therapeutically effective amount of a recombinant globin molecule that binds carbon monoxide with high affinity, wherein the recombinant globin molecule comprises:
a human recombinant neuroglobin with a H64Q, H64L, H64A or H64W mutation, and further comprising a C46G mutation, a C55S mutation and a C120S mutation; or
a human recombinant cytoglobin with a H81Q, H81A, H81L or H81W mutation, and further comprising a C38S mutation and a C83S mutation,
thereby treating carboxyhemoglobinemia in the subject.
2. The method of claim 1 , wherein the human recombinant neuroglobin comprises the amino acid sequence of SEQ ID NO: 3.
3. The method of claim 1 , wherein the human recombinant cytoglobin comprises the amino acid sequence of SEQ ID NO: 6.
4. The method of claim 1 , wherein the subject has at least 3% carboxyhemoglobin in their blood.
5. The method of claim 1 , wherein the recombinant globin molecule is administered by intravenous infusion.
6. A method of removing carbon monoxide from hemoglobin in blood or tissue, comprising contacting the blood or tissue with a recombinant globin molecule that binds carbon monoxide with high affinity, wherein the recombinant globin molecule comprises:
a human recombinant neuroglobin with an H64Q, H64L, H64A or H64W mutation, and further comprising a C46G mutation, a C55S mutation and a C120S mutation; or
a human recombinant cytoglobin with an H81Q, H81A, H81L or H81W mutation, and further comprising a C38S mutation and a C83S mutation,
thereby removing carbon monoxide from hemoglobin in the blood or tissue.
7. The method of claim 6 , wherein the human recombinant neuroglobin comprises the amino acid sequence of SEQ ID NO: 3.
8. The method of claim 6 , wherein the human recombinant cytoglobin comprises the amino acid sequence of SEQ ID NO: 6.
9. The method of claim 6 , which is an in vitro method.
10. The method of claim 6 , which is an in vivo method, wherein contacting the blood or tissue with a recombinant globin molecule comprises administering the recombinant globin molecule to a subject.
11. The method of claim 10 , wherein the subject has at least 5% carboxyhemoglobin in their blood.
12. The method of claim 10 , wherein the recombinant globin molecule is administered by intravenous infusion.
13. A human recombinant globin molecule comprising:
a human recombinant neuroglobin comprising a mutation at residue 64, and further comprising a C46G mutation, a C55S mutation and a C120S mutation; or
a human recombinant cytoglobin comprising a mutation at residue 81, and further comprising a C38S mutation and a C83S mutation.
14. The human recombinant globin molecule of claim 13 , wherein the mutation at residue 64 of the human recombinant neuroglobin is a H64Q, H64L, H64A or H64W mutation; or wherein the mutation at residue 81 of the human recombinant cytoglobin is a H81Q, H81A, H81L or H81W mutation.
15. The human recombinant globin molecule of claim 14 , comprising the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 6.
16. A composition comprising the human recombinant globin molecule of claim 13 and a pharmaceutically acceptable carrier.
17. The human recombinant globin molecule of claim 14 , wherein the human recombinant globin molecule is in monomeric form.
18. The composition of claim 16 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a wetting agent, an emulsifying agent, a preservative, and a pH buffering agent.
19. The composition of claim 16 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sodium acetate and sorbitan monolaurate.
20. The composition of claim 16 , wherein the human recombinant globin molecule is present in a therapeutically effective amount.